Overview | Agenda/Faculty Materials | Promotional Opportunities
Brochure | Administration | Speaking Proposals | Past Events | Contact Us | Home




OVERVIEW

Comparative effectiveness research (CER) is a broad concept that includes different methods for synthesizing existing evidence and for generating new evidence through a variety of types of research studies. The goal is to help identify which test or treatment options work best for different kinds of patients. In addition to improving the outcomes for individual patients, this research, it is hoped, will give all health care stakeholders the means to make decisions and set policies that will ultimately shift care to higher-value options across the health care system.

The recent federal stimulus legislations provided $1.1 billion to be distributed to the Department of Health and Human Services, the National Institutes of Health and the Agency for Healthcare Research and Quality to finance CER, including funding for studies and for the development of patient databases and other data-collecting tools.

Some medical researchers, consumer groups, unions, insurance companies and others that support such research say that it is one way to eliminate ineffective treatments and reduce federal health spending. Opponents of comparative effectiveness research - which include some pharmaceutical and medical device manufacturers, medical trade groups and consumer groups - have expressed concern that the research could lead to rationed health care, inadequate treatment for some patients like those in minority groups and restrict efforts at personalized medicine.

The purpose of the National Comparative Effectiveness Summit is to provide an overview of the current status of comparative effectiveness research in the United States, to draw lessons for the CER experience in other countries and to identify the practical implications of CER for various actors in the healthcare marketplace, including payors and health plans, hospital and health systems, physician organizations, clinicians and other healthcare professionals and pharmaceutical, biotechnology and medical device manufacturers.

Who Should Attend:
  • Employers and Other Payors
  • Health Plan Representatives
  • Hospital and Health System Representatives
  • Medical Group and IPA Representatives
  • Healthcare Group Purchasing Organization Representatives
  • Healthcare Executives and Administrators
  • Clinicians and Other Healthcare Professionals
  • Healthcare Compliance Professionals and Legal Counsel
  • Pharmaceutical, Biotech and Medical Device Manufacturers
  • Disease Management and Health Promotion Companies
  • Information Technology Vendors
  • Consumer/Patient Advocates
  • Academics
  • State and Federal Regulatory Officials
  • Capitol Hill Staff
  • Administration and Congressional Representatives
  • Health Service Researchers
  • Health Policy Experts
Featuring:
    SPECIAL PRECONFERENCE SESSION:
    Assuring that Comparative Effectiveness Research Extends to Treatment Delivery Methods, including Inpatient Hospitalist and Chronic Care Delivery Methods

    AND SPECIAL SESSIONS ON:
    • Methods and Data Infrastructure Needed for Comparative Effectiveness Research
    • The Advantages of Comparative Effectiveness Research
    • The Limits of Comparative Effectiveness Research
    • An Overview of Federal Stimulus Funding of Comparative Effectiveness Research
    • The Role of AHRQ, HHS and NIH in Comparative Effectiveness Research
    • Seeking Effectiveness in Health Care Reform: What's at Play in Washington?
    • The International Experience in Comparative Effectiveness Research
    • Comparing Effectively:The Role of Registries in Comparative Effectiveness Research
    • How States are Already Using Comparative and Cost-effective Research to Make Policy Decisions
    • Balancing Act: CER and Innovation in U.S. Health Care
    • The Implications of CER to Pharmaceutical Manufacturers
    • The Implications of CER to Medical Device Manufacturers
    • The Implications of CER for Private Health Insurers: Will it Impact Coverage and Payment?
    • Operational CER in a Medicare Health Plan to Develop Effective and Efficient Delivery Systems and Clinical Programs
    • The Implications of CER for Health System Group Purchasing Organizations
    • Motivations and Incentives for Clinicians to Develop and Use CER Best Practices
    • Can Consumers Use Comparative Effectiveness Information Effectively?




Overview | Agenda/Faculty Materials | Promotional Opportunities
Brochure | Administration | Speaking Proposals | Past Events | Contact Us | Home




© Health Care Conference Administrators
Contact Webmaster